CME Group (Nasdaq: CME) outlines client pricing changes via Special Executive Report 9676

Rhea-AI Filing Summary

CME Group Inc. filed an 8-K to note that on February 2, 2026 it communicated pricing changes to its clients through Special Executive Report 9676. The company states that a copy of this pricing notice has been posted to its website.

The disclosure is furnished under Item 7.01, meaning it is treated as information provided for Regulation FD purposes. CME Group clarifies that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated into other securities law filings unless specifically referenced.

false000115637500011563752026-02-022026-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

_________________________________________________________

FORM 8-K

_________________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) February 2, 2026 (February 2, 2026)

 _________________________________________________________

CME GROUP INC.

(Exact Name of Registrant as Specified in its Charter) 

_________________________________________________________ 

Delaware

001-31553

36-4459170

(State or Other Jurisdiction of Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

20 South Wacker Drive

Chicago

Illinois

60606

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (312) 930-1000

N/A

(Former Name or Former Address, if Changed Since Last Report) 

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Class A Common Stock			CME			Nasdaq

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On February 2, 2026, CME Group Inc. communicated pricing changes to its clients via Special Executive Report 9676. A copy of this notice has been posted to the Company’s website.

The information furnished under Item 7.01 of this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information furnished under Item 7.01 of this report shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit

Number         Description

104         The cover page from CME Group Inc.’s Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CME Group Inc.

Registrant

Date: February 2, 2026

By:

/s/ Lynne Fitzpatrick

Name: Title:

Lynne Fitzpatrick Senior Managing Director, President and Chief Financial Officer Principal Financial Offer and Duly Authorized Officer

FAQ

What did CME (CME) disclose in its latest 8-K filing?

CME Group Inc. disclosed that it communicated pricing changes to clients via Special Executive Report 9676. The company also indicated that a copy of this pricing notice has been posted on its website and that the disclosure is furnished under Item 7.01 for Regulation FD purposes.

When did CME (CME) communicate its pricing changes to clients?

CME Group Inc. communicated its pricing changes to clients on February 2, 2026. This timing is specified as both the date of the report and the earliest event reported, tied to the issuance of Special Executive Report 9676 describing the updated pricing information to market participants.

How were CME (CME) pricing changes communicated to clients?

CME Group Inc. used Special Executive Report 9676 to communicate pricing changes to clients. The company notes that this special executive report was the vehicle for the update and that a copy of the notice describing the pricing changes has been posted to CME Group’s corporate website.

Where can clients find CME (CME) Special Executive Report 9676?

CME Group Inc. states that a copy of Special Executive Report 9676, which details pricing changes, has been posted to the company’s website. Clients and investors can review the posted notice online to understand the nature of the pricing update communicated on February 2, 2026.

Is CME (CME) pricing-change information considered “filed” with the SEC?

No. CME Group Inc. specifies that information provided under Item 7.01, including the pricing changes in Special Executive Report 9676, is furnished not filed. As a result, it is not subject to Section 18 Exchange Act liabilities and is only incorporated by reference if expressly stated.

Who signed CME (CME) 8-K related to pricing changes?

The 8-K related to pricing changes was signed on behalf of CME Group Inc. by Lynne Fitzpatrick. Her title in the document is Senior Managing Director, President and Chief Financial Officer, and she is identified as the Principal Financial Officer and a duly authorized officer of the company.